GlassScriptPhysician profile
Jean C Evans
NPI 1649894908
$1,235.35
in general payments reported to CMS, 2019-2025
19 companies · $477 in 2025
The $477 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $146 · 2022: $77.18 · 2023: $85.51 · 2024: $450 · 2025: $477.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,013.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,012.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $273.18 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $132.55 | 2024-2025 | Farxiga |
| Novo Nordisk INC | $132.23 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Genentech USA, INC. | $126.99 | 2021 | |
| Pfizer INC. | $107.98 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $97.32 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $58.79 | 2024-2025 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.48 | 2024 | Synjardy, Jardiance |
| Lilly USA, LLC | $36.22 | 2024 | Mounjaro, Jardiance, Zepbound |
| Idorsia Pharmaceuticals US INC | $33.39 | 2024 | Quviviq |
| Bayer Healthcare Pharmaceuticals INC. | $32.35 | 2021-2024 | |
| Sumitomo Pharma America, INC. | $22.18 | 2025 | Gemtesa |
| Shield Therapeutics INC | $21.05 | 2025 | |
| Phadia US INC. | $18.96 | 2025 | Immunocap |
| Amneal Pharmaceuticals LLC | $18.74 | 2025 | Unithroid |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $18.49 | 2024 | Otezla, Repatha |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.28 | 2025 | Caplyta |
| Phathom Pharmaceuticals, INC. | $16.40 | 2025 | Voquezna |
| Glaxosmithkline, LLC. | $14.77 | 2024 | Shingrix, Arexvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jean Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.